Is BMA a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Argentina disinflation and rate normalization, with revenue (ttm) at ~ARS 4.26T. The bear case rests on argentina carries some of the highest macro risk of any major economy, and BMA concentrates that risk in a single stock. Analysts covering it are spread from $85.42 to $128.45, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Argentina carries some of the highest macro risk of any major economy, and BMA concentrates that risk in a single stock. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $85.42, +33.4% from the $64.04 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Argentina disinflation and rate normalization. The core driver is Argentina's path from very high inflation toward a more stable regime. The most optimistic analyst target on BMA is $128.45, +100.6% from the $64.04 price. That figure is only reachable if this thesis works close to its best case.

Argentina carries some of the highest macro risk of any major economy, and BMA concentrates that risk in a single stock. The peso can devalue sharply, which erodes US-dollar-denominated ADR value even when peso earnings look fine. Inflation, capital controls, government policy shifts, and sovereign stress all feed directly into the bank's results and its accounting (which uses inflation adjustment). Earnings have been volatile quarter to quarter (a loss in Q3 2025, then sharp beats in 2026), and the ADR has swung from a 52-week high near $106 to a low near $51, so valuation and political risk can both bite. The trailing payout ratio is near 100% of earnings, so the roughly 7% yield depends on profits continuing to recover. The most pessimistic published target is $85.42, +33.4% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Banco Macro (NYSE: BMA) is one of the largest privately owned banks in Argentina, with a national branch footprint and a strong presence outside Buenos Aires in the country's inter

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Argentina disinflation and rate normalization) stalling in the reported numbers rather than in the narrative, the risk above (argentina carries some of the highest macro risk of any major economy, and BMA concentrates that risk in a single stock) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

BMA is the New York Stock Exchange ADR of Banco Macro S.A., a large private-sector Argentine bank. Each ADR represents ten Class B common shares, so it gives US investors a way to hold an Argentine bank in dollars. As of October 16, 2026 it closed near $63.88, for a market cap near $4.1 billion.

It is a full-service bank offering retail and commercial banking, loans to individuals and small and medium businesses, deposits, and payments. It has a national footprint with particular strength in Argentina's interior provinces.

No. Banco Macro is an Argentine company. BMA is simply its ADR listed in the US, so the underlying business, currency, and regulation are all Argentine even though the shares trade in New York in dollars.